COMMUNIQUÉS West-GlobeNewswire
-
BioSyent to Present at Planet MicroCap Las Vegas
15/06/2026 -
Sienna Announces June Dividend
15/06/2026 -
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
15/06/2026 -
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026 -
KFSH Highlights Provider Transformation Through Measurable Operational Impact at HLTH Europe 2026
15/06/2026 -
Porosome Therapeutics Announces Global Drug Development Partnership with the Largest Governmental R&D Organization in India
15/06/2026 -
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
15/06/2026 -
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026 -
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
15/06/2026 -
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026 -
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026 -
Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec
15/06/2026 -
BVI Expands Commitment to Ophthalmic Education with New Experience Hub in Europe
15/06/2026 -
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
15/06/2026 -
Le KFSH met en avant la transformation des prestataires grâce à un impact opérationnel mesurable au HLTH Europe 2026
15/06/2026 -
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
15/06/2026 -
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
15/06/2026 -
AI is changing what is possible in the $10 trillion food industry. Anterra Capital is backing what comes next.
15/06/2026 -
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026
Pages